WO2014189335A1 - Protéine de fusion comprenant une protéine de liaison à l'annexine a1, protéine p53 et protéine p18 ou p16, et composition pour la prévention ou le traitement du cancer, la comprenant - Google Patents
Protéine de fusion comprenant une protéine de liaison à l'annexine a1, protéine p53 et protéine p18 ou p16, et composition pour la prévention ou le traitement du cancer, la comprenant Download PDFInfo
- Publication number
- WO2014189335A1 WO2014189335A1 PCT/KR2014/004644 KR2014004644W WO2014189335A1 WO 2014189335 A1 WO2014189335 A1 WO 2014189335A1 KR 2014004644 W KR2014004644 W KR 2014004644W WO 2014189335 A1 WO2014189335 A1 WO 2014189335A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- cancer
- fusion protein
- domain
- annexin
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 139
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 138
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 title claims abstract description 65
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 40
- 201000011510 cancer Diseases 0.000 title claims abstract description 40
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title description 9
- 108091008324 binding proteins Proteins 0.000 title description 4
- 102000000412 Annexin Human genes 0.000 title description 3
- 108050008874 Annexin Proteins 0.000 title description 3
- 102100022151 Ragulator complex protein LAMTOR1 Human genes 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 title 1
- 102000004145 Annexin A1 Human genes 0.000 claims abstract description 56
- 108090000663 Annexin A1 Proteins 0.000 claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 158
- 102000004169 proteins and genes Human genes 0.000 claims description 152
- 210000004027 cell Anatomy 0.000 claims description 58
- 102000044159 Ubiquitin Human genes 0.000 claims description 44
- 108090000848 Ubiquitin Proteins 0.000 claims description 44
- 230000000087 stabilizing effect Effects 0.000 claims description 34
- 239000012528 membrane Substances 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 238000001727 in vivo Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 210000004899 c-terminal region Anatomy 0.000 claims description 19
- 238000000338 in vitro Methods 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000001086 cytosolic effect Effects 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 230000006641 stabilisation Effects 0.000 claims description 9
- 238000011105 stabilization Methods 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 7
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 6
- 102000018697 Membrane Proteins Human genes 0.000 claims description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims description 6
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 102000007562 Serum Albumin Human genes 0.000 claims description 5
- 108010071390 Serum Albumin Proteins 0.000 claims description 5
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- -1 SUM 1 Proteins 0.000 claims description 3
- 102100026940 Small ubiquitin-related modifier 1 Human genes 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 101100153168 Arabidopsis thaliana TIC21 gene Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 101100273813 Homo sapiens CDKN1A gene Proteins 0.000 claims description 2
- 101000662278 Homo sapiens Ubiquitin-like protein 3 Proteins 0.000 claims description 2
- 101000772767 Homo sapiens Ubiquitin-like protein 5 Proteins 0.000 claims description 2
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000002231 Muscle Neoplasms Diseases 0.000 claims description 2
- 102100031911 NEDD8 Human genes 0.000 claims description 2
- 101150107958 NEDD8 gene Proteins 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 108700038981 SUMO-1 Proteins 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 101100083337 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pic1 gene Proteins 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 102100024542 Small ubiquitin-related modifier 2 Human genes 0.000 claims description 2
- 101710081711 Small ubiquitin-related modifier 2 Proteins 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 102100037847 Ubiquitin-like protein 3 Human genes 0.000 claims description 2
- 102100030580 Ubiquitin-like protein 5 Human genes 0.000 claims description 2
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 201000002077 muscle cancer Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 claims 1
- 101000898291 Nicotiana tabacum Catalase isozyme 1 Proteins 0.000 claims 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 claims 1
- 101000979255 Sus scrofa Neurolysin, mitochondrial Proteins 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 129
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000004663 cell proliferation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 9
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 6
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 108020005091 Replication Origin Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 235000001465 calcium Nutrition 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000004952 protein activity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 101150024147 bax gene Proteins 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 102000011961 Maturation-Promoting Factor Human genes 0.000 description 2
- 108010075942 Maturation-Promoting Factor Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 102000022032 p53 binding proteins Human genes 0.000 description 2
- 108091012362 p53 binding proteins Proteins 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WNGZKSVJFDZICU-XIRDDKMYSA-N Asp-Leu-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N WNGZKSVJFDZICU-XIRDDKMYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000012746 DNA damage checkpoint Effects 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000970017 Homo sapiens NEDD8 ultimate buster 1 Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102100021741 NEDD8 ultimate buster 1 Human genes 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 101710081623 Small ubiquitin-related modifier 1 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ABWNZPOIUJMNKT-IXOXFDKPSA-N Thr-Phe-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O ABWNZPOIUJMNKT-IXOXFDKPSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010056354 Ubiquitin C Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000026374 cyclin catabolic process Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000006333 protein structural change Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000016596 traversing start control point of mitotic cell cycle Effects 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4728—Calcium binding proteins, e.g. calmodulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Definitions
- Fusion protein comprising annexin A1 binding protein, p53 protein, and pl8 or pl6 protein and composition for preventing or treating cancer comprising the same
- the present invention relates to an anneal A1 binding protein, a p53 protein, and a fusion protein to which a pl8 or pl6 protein is bound, preparation of the fusion protein, and a pharmaceutical composition for preventing or treating cancer comprising the fusion protein.
- CDK cyclin-dependent kinase
- Cyclin-CD complex phosphorylates proteins involved in cell proliferation, resulting in cell division. Induce. Proteins that induce DNA replicators are mainly Cyclin D / E and CDK 4/6, and CDK 4/6 phosphorylates Rb (Retinoblastoma) protein to transcription of transcription factor E2F. Make it active. The proteins that induce cell division are mainly Cyclin A / B and CDK 2/1, and their Cyclin-CDK complex is called MPF (M-phase promoting factor).
- MPF M-phase promoting factor
- p21 protein that act as all been 'DNA damage checkpoint in G1.
- the p21 gene is expressed by p53, a tumor suppressor gene that is activated when DNA is damaged.
- p21 binds to the Cyclin-CDK complex that induces a DNA replicator and inhibits the kinase activity of CDK4 / 6/2, thereby preventing phosphorylation of the Rb protein.
- the cells stay in G1 phase and have time to repair damaged DNA. If the DNA damage is severely unacceptable to cells, p53 expresses the gene of Bax protein, an apoptosis-inducing gene.
- the action of p53 in the regulation of cell proliferation is to express p21 gene to temporarily stop cell proliferation, or p53 protein combined with ASPP protein, which is a p53-binding protein, expresses Bax gene. It can be divided into two things: apoptosis inducing. Apoptosis, also known as programmed cell death, is when cell death is beneficial at the individual level, such as when cells are no longer needed in the tissue, when they have been invaded by a virus or when they have been converted into cancer cells. It is a mechanism to commit suicide by itself.
- CDK inhibitors that regulate cell cycle can be classified into two groups, CIP CDK inhibitor protein family and INK4 (Inhibitors of cyclin-dependent kinase 4).
- CIP has p21 and p27.
- INK4 mainly inhibits the activity of CDK 4, 6, and there are pl5, pl6, pl8 and pl9.
- a balance between the tumor suppressor gene and the proto-oncogene In order to regulate cell proliferation, a balance between the tumor suppressor gene and the proto-oncogene must be maintained. Mutation of the gene of the p53 protein, a tumor suppressor gene, leads to abnormal cell proliferation because it cannot induce apoptosis of abnormal cells. Also Precancerous genes, which are normal cell proliferation factors, are mutated (such as viral gene replacement) or overexpressed to become cancer genes, leading to abnormal cell proliferation such as cancer cells.
- the oncogene causes growth of cells with abnormal activity, intracellular signaling proteins, and thus causes false signal transduction, so that cell proliferation occurs even without external proliferation signals.
- One embodiment provides a fusion protein comprising an annexin A1 binding protein, a .p53 protein or fragment thereof, and a pl8 or pl6 protein.
- Another embodiment provides a polynucleotide encoding the fusion protein.
- Another embodiment provides a recombinant vector comprising the polynucleotide.
- Another embodiment provides a cell transformed with the recombinant vector.
- Another embodiment provides a method of preparing a fusion protein comprising culturing the transformed cells.
- Another embodiment provides a pharmaceutical composition for preventing and / or treating cancer comprising the fusion protein as an active ingredient.
- Another embodiment provides a method of treating cancer comprising administering to a subject a therapeutically effective amount of said fusion protein.
- FIG. 1 schematically shows an example of a fusion protein according to one embodiment.
- 2 is a result showing that the fusion protein (protein complex # 1) binds to annexin A1 according to one embodiment, (1) is a result in the absence of calcium ions, (2) is a calcium ion The results are shown under these existing conditions.
- Figure 3 shows the results confirming the cell growth inhibition effect according to the treatment concentration of the fusion protein (protein complex # 1) in HCC1806 cell line.
- Figure 4 shows the results confirming the cell growth inhibition effect according to the treatment concentration of the fusion protein (protein complex # 1) in HCC116 cell line. [Best form for implementation of the invention]
- a fusion protein comprising annexin A1 binding protein, p53 protein or fragment thereof, and pl8 or pl6 protein.
- the fusion protein may be an in vitro stabilization protein, a membrane transfer sequence (MTS) domain, a nuclear-cytoplasm signal domain, and an in vivo stabilization protein. It may further comprise one or more selected from the group consisting of.
- Another example provides a polynucleotide encoding the fusion protein.
- Another example provides a recombinant vector comprising the polynucleotide.
- Another example provides a cell transformed with the recombinant vector.
- Another example provides a method for producing a fusion protein comprising culturing the transformed cells.
- compositions for preventing and / or treating cancer comprising the fusion protein as an active ingredient.
- the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, diluent and / or excipient in an amount normally used as necessary.
- CDK (Cyclin-dependent kinase) protein plays a major role in cancer development, and as an inhibitor thereof CIP (CDK inhibitor) protein lineage protein and INK4 (inhibitors of cyclin—dependent kinase 4) lineage proteins.
- the fusion protein according to one embodiment of the present invention is a p53 protein that regulates CIP strain protein expression and pl8 or pl6 protein belonging to the INK4 strain protein, and simultaneously exerts CIP strain protein activity and INK4 protein activity to improve cancer. Prophylactic and / or therapeutic effects may be obtained.
- the p53 protein may be a polypeptide or fragment thereof having an amino acid sequence provided by NCBI accession number NPJD00537.
- P53 protein is used herein to mean both full-length protein and fragments thereof unless otherwise stated.
- the p53 protein may be a transcriptional activation domain of p53 protein having the amino acid sequence of SEQ ID NO: KGlu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn).
- the p53 protein fragment having the amino acid sequence of SEQ ID NO: 1 means a transcriptional active domain comprising the 18th to 26th amino acid sequence of the human p53 protein, which is a site that binds to Mdm2 in the p53 protein.
- the transcriptional activation domain of p53 significantly increases the stability of p53 in vivo by binding to Mdm2, which is responsible for p53 degradation, and expresses p21 gene encoding CDK inhibitor protein by p53 to temporarily stop cell proliferation.
- p53 combined with the apoptosis-stimulating protein of p53 (ASPP), a p53-binding protein, expresses the Bax gene and causes cell death.
- tumor suppressor pl8 or pl6 protein plays a role in inhibiting the activity of CDK 4, 6. Therefore, the fusion protein in which the transcriptional activation domain of p53 and the pl8 or pl6 protein are combined and the pharmaceutical composition containing the same as an active ingredient can be used as a novel anticancer agent.
- the pl8 protein may be a polypeptide having an amino acid sequence of SEQ ID NO: 2.
- the pl8 protein may be used by modifying (substituting, deleting, adding, deleting, etc.) some amino acid residues for the purpose of improving solubility, so long as it does not affect the overall protein activity.
- the pl6 protein may be a polypeptide having an amino acid sequence of SEQ ID NO: 3.
- the pl6 protein may be used by modifying (substituting, deleting, adding, deleting, etc.) some amino acid residues so long as it does not affect the overall protein activity for the purpose of improving solubility.
- sequence of linking the p53 protein and pl8 or pl6 protein in the fusion protein is not limited, and includes both N-terminal -p53 protein -pl8 or pl6 protein -C terminus or N-terminal -pl8 or pl6 protein -p53 protein_C terminus forms.
- p53 protein fragments and pl8 protein binding fusion protein may be one having the amino acid sequence of SEQ ID NO: 4, p53 protein fragments and pl6 protein binding fusion protein having an amino acid sequence of SEQ ID NO: 5 It may be.
- the fusion protein of the present invention includes the Annexin A1 binding protein (Annexin A1BP) ol.
- Annexin A1 binding protein binds to Annexin A1, which is specifically expressed in cancer cells, thereby enabling cancer cell targeting so that the fusion protein can selectively act only on cancer cells.
- Annexin A1 binding protein may be exemplified by a peptide having an amino acid sequence selected from SEQ ID NO: 6 to SEQ ID NO: 14, but the scope of the present invention is not limited thereto, as long as it can achieve cancer cell targeting activity Fragments, peptides, analogs or variants of the A1 binding protein may be used.
- the annexin A1 binding protein in the fusion protein may be located at the N-terminus or C-terminus of the p53 and pl8 or pl6 fusions.
- the fusion protein of the present invention may include an annexin A1 binding protein p53 protein, and a pl8 or ⁇ protein in the order of ⁇ -terminal to C-terminal; A fusion protein comprising an annexin A1 binding protein, ⁇ 18 or ⁇ 16 protein, and ⁇ 53 protein in the N-terminal order of the C-terminus; a fusion protein comprising a ⁇ 53 protein, a ⁇ 18 or ⁇ 16 protein, and an annexin A1 binding protein in the order of ⁇ -terminal to C-terminal; a fusion protein comprising a ⁇ 18 or ⁇ 16 protein, a ⁇ 53 protein and an annexin A1 binding protein in the order of ⁇ -terminal to C-terminal It may be.
- At least one member selected from the group consisting of in vitro stabilization protein, membrane transfer sequence (MTS) domain, nucleus-cytoplasm signal domain, and in vivo stabilization protein May include additional additions.
- the position of the added polypeptide in the fusion protein is not limited, and the one or more polypeptides to be added may be included independently of the N-terminal, C-terminal, or p53 protein and pl8 or pl6 protein of the fusion protein. have.
- the fusion protein is stabilized in vitro in the N-terminal direction of the p53 protein in the fusion protein comprising an annexin A1 binding protein, p53 protein, and pl8 or pl6 protein in the N-terminal to C-terminal order Protein, membrane transmembrane sequence domain and nuclear-cytoplasmic signal domain, further comprising at least one selected from the group consisting of membrane permeable sequence domain, nuclear-cytoplasmic signal domain, and in vivo in the C-terminal direction of pl8 or pl6 protein. It may further comprise one or more selected from the group consisting of stabilizing proteins.
- the fusion protein may include an annexin A1 binding protein, a pl8 or pl6 protein, and a p53 protein in the order of N-terminus to C-terminus, in the ⁇ —terminal direction of the pl8 or ⁇ 16 protein. It further comprises one or more selected from the group consisting of an in vitro stabilizing protein, a membrane permeation sequence domain and a nuclear-cytoplasmic signal domain, or a membrane permeation sequence domain, a nuclear-cytoplasmic signal domain and a biomarker in the C—terminal direction of the ⁇ 53 protein. It may further comprise one or more selected from the group consisting of a stabilizing protein.
- the fusion protein may comprise a ⁇ 53 protein, a ⁇ 18 or ⁇ 16 protein, and an annexin A1 binding protein, in the order of ⁇ -terminal to C-terminal, in the ⁇ -terminal direction of the annexin A1 binding protein. Further comprises at least one member selected from the group consisting of an in vitro stabilizing protein, a membrane permeation sequence domain and a nuclear-cytoplasmic signal domain, or is Annexin A1.
- the c-terminal direction of the binding protein may further include one or more selected from the group consisting of a membrane permeation sequence domain, a nuclear-cytoplasmic signal domain, and an in vivo stabilizing protein.
- the fusion protein may comprise a pl8 or pl6 protein, a p53 protein, and an annexin A1 binding protein in the order of N-terminus to C-terminus.
- Direction further comprises at least one member selected from the group consisting of an in vitro stabilizing protein, a membrane permeation sequence domain and a nuclear-cytoplasmic signal domain, or a membrane permeation sequence domain, a nuclear- in the C-terminal direction of an annexin A1 binding protein. It may further comprise one or more selected from the group consisting of a cytoplasmic signal domain and an in vivo stabilizing protein.
- the term “in vitro stabilization protein” refers to a protein for enhancing the solubility and stability of the fusion protein outside of the fusion protein, that is, when the fusion protein is experimentally purified. Means.
- the ex vivo stabilizing protein is part of the fusion protein and should not induce immunogenicity in vivo.
- the ex vivo stabilizing protein when introduced into the fusion protein, it is preferably located in the N-terminal direction of the fusion protein, but is not limited thereto.
- the ex vivo stabilizing protein may additionally be located between pl8 and p53 in addition to both ends of the fusion protein.
- the in vitro stabilizing protein may be, but is not limited to, ubiquitin or ubiquitin-like protein.
- Ubiquitin (Ub) is the most conserved protein found in nature and consists of 76 amino acid sequences and is a water soluble protein that shows perfect homology between evolutionarily diverse species such as insects, trout and humans. Ubiquitin is also known as a protein that is stable to changes in pH, is not easily denatured even at high temperatures, and is stable to proteases. Thus, ubiquitin can improve the insolubility of the fusion protein.
- the ubiquitin or ubiquitin-like protein is wild type ubiquitin, wild type ubiquitin-like protein, mutant ubiquitin And mutant ubiquitin-like protein may be selected from the group consisting of.
- the mutant ubiquitin means that the amino acid sequence of the wild type ubiquitin is changed to another amino acid sequence, for example, ubiquitin in which Lys of wild type ubiquitin (SEQ ID NO: 15) is replaced with Arg, and / or wild type ubiquitin C ⁇ terminal RGG is RGA.
- Ubiquitin ie, Gly present at 76th of the ubiquitin wild-type polypeptide is substituted with Ala).
- the substitution is at least one selected from Lys present in 6, 11, 27, 29, 33, 48 and 63 of the wild type ubiquitin. And substitutions may be made independently or in combination at the positions of Lys.
- the ubiquitin-like protein is a protein having similar characteristics to ubiquitin, for example, Nedd8, SUMO-1, SUMO-2, NUB1, PIC1, UBL3, UBL5 and ISG15 selected from the group consisting of It may be more than one, but is not limited thereto.
- the ubiquitin or ubiquitin-like protein is
- the C-terminus may comprise an amino acid sequence cleavable by the protease or an amino acid sequence not cleaved by the protease.
- Amino acid sequences cleavable by the protease can be identified through a search database known in the art. For example, a protease and a cleavable amino acid sequence thereof can be used which is searched for at http://www.expasy.org/tools/peptidecutter/peptidecutter—enzymes.html.
- the fusion protein is permeated into the cell, and then the ubiquitin or ubiquitin-like protein is cleaved by a protease in the cell, and includes annexin A1 binding protein, p53 protein, and pl8 or pl6 protein.
- the fusion protein is able to function in the cell.
- the fusion protein may contain membrane transmembrane sequence domains and / or nuclear-cytoplasmic signal domains, but since these polypeptides are very short in length, they do not affect the function of the fusion protein.
- ubiquitin or ubiquitin-like proteins are not cleaved, ubiquitin or ubiquitin-like proteins are safe in vivo because they are not immunogenic, and because they do not fold because they do not contain cysteine, they do not cause fusion protein structural changes and the fusion proteins do not change in cells. It does not affect the function.
- membrane transfer refers to the ability to transport a fusion protein to be delivered intracellularly and / or in vivo in vitro and / or in vivo.
- membrane transfer sequence (MTS) domain means a polylapide having an amino acid sequence that can itself pass through the cell membrane of a phospholipid bilayer.
- the membrane permeable sequence domain has a single hydrophobic region at its N-terminus, forms a helix structure, exhibits flexibility, and has a relatively short length of amino acids (7 to 17 amino acids). Characterized in having a.
- the physical properties of the membrane permeable sequence domains usually exhibit hydrophobicity.
- the membrane permeable sequence domain may be any polypeptide having an amino acid sequence that can pass through the cell membrane of the phospholipid bilayer per se and is not particularly limited, but may be composed of the amino acid sequence of SEQ ID NO: 16 .
- the transmembrane sequence domain when introduced into the fusion protein, it is preferably located in the N terminal direction of the fusion protein, but is not limited thereto.
- nucleus-cytoplasm signal domain is interpreted to mean a polydide sequence that serves to transport fusion proteins into or out of the nucleus.
- the nuclear cell cytoplasmic signal domain may be a NLSCnucleus location sequence (NLSCnucleus location sequence) domain or NES (nucleus export sequence) domain. That is, NLS may be included in the fusion protein to transfer the fusion protein into the nucleus, and NES may be included in the fusion protein in order to keep the fusion protein in the cytoplasm.
- NLS domains are proteins that are transported from the cytoplasm to the nucleus
- NES domains are characterized by proteins that are transported from the nucleus to the cytoplasm, all of which refer to polypeptides having an amino acid sequence that can pass through the nuclear membrane.
- the polypeptide which may be used as the NLS domain is not particularly limited.
- the polypeptide may be KKKRK (SEQ ID NO: 17), PKKKRKV (SEQ ID NO: 18), KRPAATKKAGQAKKKK (SEQ ID NO: 19), and the like. .
- the nuclear-cytoplasmic signal domain in the fusion protein plays an important role in increasing the solubility of the protein, in addition to the important task of moving the fusion protein into and out of the nucleus, where it is located close to the C-terminus of the fusion protein. It is more helpful for the increase.
- the term “in vivo stabilization protein” refers to a protein that provides stability to the fusion protein stably in a living body in which the fusion protein substantially acts.
- the protein is a part of the fusion protein, and should not induce immunogenicity in vivo, and in particular, any protein can be used as long as it can obtain stability in the blood of the subject.
- the in vivo stabilizing protein may be at least one selected from the group consisting of AAT (alpha 1 antitrypsin), serum albumin, serum albumin binding peptide (SABP), immunoglobulin Fc and PEG (polyethyleneglycol).
- the in vivo stabilizing protein is fused. When incorporated into the protein, it may also be implemented between the N-terminal, C-terminal or the p53 protein and pl8 protein of the fusion protein.
- a stop codon may be further included.
- the stop codon may be inserted repeatedly two or more times, for example, a TAA sequence may be inserted twice.
- STOPx2 the case where the stop codon is inserted twice is referred to as STOPx2 for convenience.
- the present invention provides an annexin A1 binding protein, p53 protein or p53 protein fragment having the amino acid sequence of SEQ ID NO: 1, and pl8 or pl6 protein It provides a pharmaceutical composition for the prevention or treatment of cancer comprising the fusion protein comprising as an active ingredient.
- the fusion protein may further include one or more selected from the group consisting of an in vitro stabilizing protein, a membrane permeation sequence domain, a nuclear-cytoplasmic signal domain, and an in vivo stabilizing protein, and the details thereof are as described above. .
- the fusion protein is a fusion protein comprising an annexin A1 binding protein, p53 protein, and ⁇ 18 or pl6 protein in the N-terminal to C-terminal order;
- a fusion protein comprising an annexin A1 binding protein, a pl8 or pl6 protein, and a p53 protein in the order of the N-terminus to the C-terminus;
- a fusion protein comprising a p53 protein, a pl8 or pl6 protein, and an annexin A1 binding protein in the order of N-terminus to C-terminus;
- the pl8 or pl6 protein, p53 protein and annexin A1 binding protein may be selected from the group consisting of a fusion protein comprising in the order of the N- terminal to the C- terminal.
- the fusion protein is an annexin A1 binding protein, p53 protein, and pl8 or pl6 protein in the fusion protein comprising N-terminal ⁇ terminal, N-terminal direction of the p53 protein Or at least one member selected from the group consisting of an ex vivo stabilizing protein, a membrane permeation sequence domain and a nuclear cytoplasmic signal domain, or a membrane permeation sequence domain, a nuclear cytoplasmic signal in the C-terminal direction of a pl8 or pl6 protein.
- a fusion protein further comprising at least one selected from the group consisting of a domain and an in vivo stabilizing protein; ,
- fusion proteins comprising annexin A1 binding protein, pl8 or pl6 protein, and p53 protein in the N-terminus to C-terminus
- membrane permeation sequence Further comprising one or more selected from the group consisting of a domain and a nuclear cytoplasmic signal domain, or selected from the group consisting of a membrane permeable sequence domain, a nuclear-cytoplasmic signal domain and an in vivo stabilizing protein in the C-terminal direction of the P53 protein.
- 1 kind A fusion protein further comprising an ideal phase
- a fusion protein comprising p53 protein, pl8 or pl6 protein, and annexin A1 binding protein in the order of N-terminus to C-terminus
- in vitro stabilizing protein membrane permeation in the N-terminal direction of annexin A1 binding protein
- It further comprises one or more selected from the group consisting of a sequence domain and a nuclear-cytoplasmic signal domain, or a membrane permeable sequence domain, a nuclear ⁇ cytoplasmic signal domain and an in vivo stabilizing protein in the C-terminal direction of the annexin A1 binding protein.
- a fusion protein further comprising one or more selected from the group consisting of; And
- a fusion protein comprising pl8 or pl6 protein, p53 protein and annexin A1 binding protein in the order of N-terminus to C-terminus
- in vitro stabilizing protein membrane permeation sequence in the N-terminal direction of annexin A1 binding protein
- membrane permeation sequence in the N-terminal direction of annexin A1 binding protein
- at least one member selected from the group consisting of a domain and a nuclear cell cytoplasmic signal domain, or a membrane permeable sequence domain, a nuclear cytoplasmic signal domain, and an in vivo stabilizing protein in the C-terminal direction of the annexin A1 binding protein It may be selected from the group consisting of a fusion protein that further comprises one or more selected from the group.
- the present invention also provides a polynucleotide encoding the fusion protein, a recombinant vector comprising the polynucleotide, and a cell transformed with the recombinant vector.
- the present invention provides a method for producing a fusion protein comprising the step of culturing the transformed cells.
- polynucleotide refers to a polymer of deoxyribonucleotides or ribonucleotides present in single- or double-stranded form. Such polynucleotides encompass RNA genomic sequences, cDNAs and RNA sequences transcribed therefrom, and include analogs of natural polynucleotides unless specifically noted otherwise.
- the polynucleotide encoding the protein complex of the present invention may be one comprising the nucleic acid sequence of SEQ ID NO: 21.
- the polynucleotide includes not only the nucleotide sequence encoding the amino acid sequence of the fusion protein but also a complementary sequence to the sequence.
- the complementary sequence is perfectly In addition to complementary sequences, it also includes substantially complementary sequences that can be hybridized with nucleotide sequences encoding, for example, the amino acid sequence of the fusion protein, under stringent conditions known in the art. Means.
- the recombinant vector may be an expression vector, which can stably express the fusion protein in a host cell.
- the expression vector may be a conventional one used to express foreign proteins in plants, animals or microorganisms in the art.
- the recombinant vector can be constructed through various methods known in the art.
- the recombinant vector can be constructed using prokaryotic or eukaryotic cells as hosts.
- a strong promoter capable of promoting transcription e.g., pLA promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.
- replication origins that operate in eukaryotic cells included in the vector include fl replication origin, SV40 replication origin, pMBl replication origin, adeno replication origin, AAV replication origin, and BBV replication origin. It is not limited.
- promoters derived from the genome of mammalian cells eg, metallothionine promoters
- promoters derived from mammalian viruses eg, adenovirus late promoters, vaccinia virus 7.5K promoters, SV40 promoters, Cytomegalovirus promoter and tk promoter of HSV
- the transformed cell may be any host cell known in the art as the host cell capable of continuously cloning or expressing the recombinant vector, and as a prokaryotic cell, for example, E. coli Bacillus genus strains such as JM109, E. coll BL21, E. coli RRl, E. coJi LE392, E. coli B, E. coli X 1776, E. co // W3110, Bacillus subtilis, Bacillus thuringiensis, And enterococci and strains such as Salmonella typhimurium, Serratia marsonsons and various Pseudomonas species.
- E. coli Bacillus genus strains such as JM109, E. coll BL21, E. coli RRl, E. coJi LE392, E. coli B, E. coli X 1776, E. co // W3110, Bacillus subtilis, Bacillus thuringiensis, And enterococci and strains such as Salmon
- Ho—SX Saccharomyce cerevisiae, stromal cells, plant cells and animal cells for example, CHO cell line (Chinese hamster ovary), W138, BHK, COS-7, 293, HepG2, 3T3, RIN And MDCK cell lines can be used.
- the delivery of the polynucleotide or recombinant vector comprising the same into a host cell may employ a delivery method well known in the art.
- a delivery method well known in the art.
- the host cell is a prokaryotic cell
- a CaCl 2 method or an electroporation method may be used.
- the host cell is a eukaryotic cell
- a micro-injection method, a calcium phosphate precipitation method, an electroporation method, a liposome -Mediated transfection and gene bombardment may be used, but is not limited thereto.
- the method of selecting the transformed host cell can be easily carried out according to methods well known in the art using a phenotype expressed by a selection label.
- the selection marker is a specific antibiotic resistance gene
- the transformant can be easily selected by culturing the transformant in a medium containing the antibiotic.
- Cultivation of the transformed cells can be carried out through various methods known in the art.
- the cells were cultured by inoculating the transformed cells in YT liquid medium, and then inducing and culturing protein expression by the / acZ promoter by adding IPTG to the medium when the cell density reached a certain level. Proteins secreted in vitro or in media can be obtained.
- Proteins secreted into cells or into the medium can be obtained in purified form according to various purification methods known in the art. In purified form, for example, by solubility fractionation with ammonium sulphate, size fractional filtration and purification by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). Protein can be obtained. For example, when the fusion protein is fused to GST, the desired protein can be easily obtained by using a resin column bound to glutathione or a Ni 2+ -NTA His-bound resin column when fused to 6x His.
- p53 and pl8 included in the fusion protein Or the pl6 fusion significantly increases the stability of p53, temporarily expresses the p21 gene and stops cell proliferation, and expresses the Bax gene to induce cell death and inhibit CDK 4, 6 activity. It is effective as an active ingredient in the prevention and / or treatment of cancer.
- annexin A1 binding protein another component included in the fusion protein, binds to annexin A1 specifically expressed in cancer cells, thereby enabling cancer cell targeting so that the fusion protein can selectively act on only cancer cells. Therefore, the fusion protein of the present invention can be provided as a pharmaceutical composition for the prevention and / or treatment of cancer.
- a pharmaceutical composition for preventing and / or treating cancer comprising the fusion protein as an active ingredient.
- the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, diluent and / or excipient in an amount normally used as necessary.
- the pharmaceutically acceptable carrier is conventionally used in the preparation, lactose, dextrose, sucrose, sorbbi, manny, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline Cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, stearic acid magnesium and mineral oils, including but not limited to no.
- the pharmaceutical composition may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspension preservative, and the like, in addition to the above components.
- a method of preventing and / or treating cancer comprising administering a therapeutically effective amount of the fusion protein to an individual in need thereof.
- the method for preventing and / or treating cancer may further comprise identifying a subject in need of ' prophylaxis and / or treatment of cancer prior to the administering step.
- use is provided for use in the prevention and / or treatment of cancer of the fusion protein, or for use in the manufacture of a medicament for the prevention and / or treatment of cancer of the fusion protein.
- the fusion protein or a pharmaceutical composition comprising the same as an active ingredient is a pharmaceutically acceptable carrier according to a method which can be easily carried out by those skilled in the art. And / or by formulating with excipients, they may be prepared in unit dose form or may be prepared within a multi-dose container.
- the formulation may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of extracts, powders, powders, granules, tablets or accelerators, and may further comprise dispersants or stabilizers.
- the composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional medical agents.
- the fusion protein or a pharmaceutical composition for preventing or treating cancer containing the same as an active ingredient may be administered orally or parenterally.
- parenteral administration it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, pulmonary administration and rectal administration.
- oral administration because proteins or peptides are digested, oral compositions should be formulated to coat the active agent or to protect it from degradation in the stomach.
- the composition may be administered by any device that allows the composition to migrate to the target cell.
- Suitable dosages of the fusion protein or a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient include a formulation method, a mode of administration, a patient's age, weight, sex, morbidity, food, time of administration, route of administration, and excretion rate. And various factors such as reaction responsiveness. Preferred dosages of the compositions are in the range of 0.001 to 100 mg / kg on an adult basis.
- pharmaceutically effective amount or “therapeutically effective amount” means an amount that can be effective in preventing or treating cancer.
- the patient to be administered the pharmaceutical composition for preventing or treating the fusion protein or cancer containing the same as an active ingredient may be a rodent including a mammal, for example, a primate including a human monkey, and the like.
- the cancer to be prevented or treated by the fusion protein or pharmaceutical composition may be solid or hematologic cancer, for example, squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, squamous cell carcinoma of the lung Peritoneal cancer, skin cancer, skin or intraocular myeloma, rectal cancer, anal muscle cancer, esophageal cancer, small intestine cancer, endocrine cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or Acute leukemia, lymphoma, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colon cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulva cancer, thyroid cancer, head and neck cancer It may be selected from the group struggled by the back, but is not limited thereto.
- one of the hydrophilic polypeptides is ubiquitin wild type protein or ubiquitin mutant protein, membrane transfer sequence (MTS), pi 8, in vivo stabilizing protein (AAT: alpha 1 antitrypsin), p53 fragment, nucleus.
- An expression vector of the protein complex was prepared to produce a protein complex for intracellular delivery linked in the order of the nucleus localization signal domain (NLS).
- an expression vector for producing a protein complex excluding one or more components from the protein complex was prepared for a comparative experiment with the protein complex.
- wild type ubiquitin was referred to as Ub
- a wild type ubiquitin C-terminal RGG was prepared.
- the mutant ubiquitin modified with RGA is called Ubml.
- a total of two kinds of expression vectors were prepared by Genotech Co., Ltd., and a vector for protein overexpression was pET-21b (+) (EMD Biosciences).
- each insert DNA fragment comprises a nucleotide sequence that can be cleaved with Ndel at the 5 'end, and a nucleotide sequence that can be cleaved with Xhol at the 3' end, Ndel-Xhol cleavage of the pET21b (+) vector Can be inserted into the sequence.
- a schematic diagram showing possible primary structures of the protein complex according to one embodiment is shown in FIG. 1.
- Example 2 Expression and Purification of Fusion Proteins
- the supernatant was obtained using a centrifuge (10,000 g). The supernatant was applied to a Ni 2+ -NTA superflow column (Qiagen) equilibrated with the complete solution, and the washed supernatant (50 mM Tris-HCl, pH 8.0, 5% glycerol) corresponding to 5 times the column volume. Wash the 5 mM ⁇ -mercaptoethane with 0.2% Triton X-100 and 1 M NaCl, and then elute the complete solution (50 mM Tris-HCl, pH 8.0, 5% glycerol, 5 mM ⁇ -mercapto).
- Example 3 Confirmation of Calcium-dependent Binding of the Fusion Protein to Annexin A1
- the protein complex # 1 and annexin A1 prepared in Example 2 contained calcium-free buffer (Tris-HCl 50 mM, 10% glycerol pH 7.6) or calcium.
- the cells were each dispensed in RPMI medium (Gibco BL) containing 10% FBS with 5> ⁇ 10 3 per well in a 96-well plate.
- the proteins were 0, 0.25, 0.5, 1, 2, 4uM and then incubated for 72 hours at a temperature of 37 0 C, C0 2 5% in a CO 2 incubator.
- the protein complex-free buffer 0.1 arginine, 0.2% Tween20, 0.2% L-Glutathione, lXPBSCpH 7.4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une protéine de fusion, dans laquelle une protéine de liaison à l'annexine A1, une protéine p53 et une protéine p18 ou p16 sont conjuguées, la préparation de la protéine de fusion, et une composition pharmaceutique pour la prévention ou le traitement du cancer, contenant la protéine de fusion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0059277 | 2013-05-24 | ||
KR20130059277A KR20140138507A (ko) | 2013-05-24 | 2013-05-24 | 아넥신 A1 결합단백질, p53 단백질, 및 p18 또는 p16 단백질을 포함하는 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014189335A1 true WO2014189335A1 (fr) | 2014-11-27 |
Family
ID=51933820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/004644 WO2014189335A1 (fr) | 2013-05-24 | 2014-05-23 | Protéine de fusion comprenant une protéine de liaison à l'annexine a1, protéine p53 et protéine p18 ou p16, et composition pour la prévention ou le traitement du cancer, la comprenant |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20140138507A (fr) |
WO (1) | WO2014189335A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10799579B2 (en) | 2015-01-16 | 2020-10-13 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9701725B2 (en) | 2003-05-05 | 2017-07-11 | The Johns Hopkins University | Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080032476A (ko) * | 2006-10-10 | 2008-04-15 | 학교법인 한림대학교 | 아넥신 융합 단백질 |
-
2013
- 2013-05-24 KR KR20130059277A patent/KR20140138507A/ko not_active Application Discontinuation
-
2014
- 2014-05-23 WO PCT/KR2014/004644 patent/WO2014189335A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080032476A (ko) * | 2006-10-10 | 2008-04-15 | 학교법인 한림대학교 | 아넥신 융합 단백질 |
Non-Patent Citations (4)
Title |
---|
BIRD ET AL.: "An autologous dendritic cell canine mammary tumor hybrid- cell fusion vaccine", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 60, no. 1, 2011, pages 87 - 97, XP019877353, DOI: doi:10.1007/s00262-010-0921-2 * |
KABIR ET AL.: "Novel frameshift mutation in the p16/INK4A tumor suppressor gene in canine breast cancer alters expression from the p16/INK4A/p14ARF locus", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 114, no. 1, January 2013 (2013-01-01), pages 56 - 66 * |
SHAW ET AL.: "Effects of loss of p53 and p16 function on life span and survival of human urothelial cells", INTERNATIONAL JOURNAL OF CANCER, vol. 116, no. 4, 2005, pages 634 - 639 * |
ZHU ET AL.: "PTEN induces G1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells", CANCER RESEARCH, vol. 61, no. 11, 2001, pages 4569 - 4575 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10799579B2 (en) | 2015-01-16 | 2020-10-13 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
US11766478B2 (en) | 2015-01-16 | 2023-09-26 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
Also Published As
Publication number | Publication date |
---|---|
KR20140138507A (ko) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102578891B1 (ko) | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 | |
Liou et al. | The NF‐kappa B p50 precursor, p105, contains an internal I kappa B‐like inhibitor that preferentially inhibits p50. | |
Ma et al. | Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements | |
Criqui et al. | Cell cycle‐dependent proteolysis and ectopic overexpression of cyclin B1 in tobacco BY2 cells | |
Gytz et al. | Apoptotic properties of the type 1 interferon induced family of human mitochondrial membrane ISG12 proteins | |
DK2661496T3 (en) | FUSION PROTEIN AS ANTICANCING AGENT | |
JPH11313686A (ja) | サイクリン依存性キナ―ゼの阻害剤の結合パ―トナ―、並びにそれらの阻害剤検索および疾病の診断または治療のための使用 | |
CN105999227B (zh) | FOXM1蛋白氮端(1-234 aa)的表达及其用途 | |
KR20160126340A (ko) | 3중-나선 다발 단백질 및 이의 용도 | |
AU2024201112A1 (en) | Composition comprising VGLL1 peptide for treatment of cancer | |
Fujihara et al. | Inhibition of NF-κB by a cell permeable form of IκBα induces apoptosis in eosinophils | |
Yoo et al. | JAB1 regulates CPNE1-related differentiation via direct binding to CPNE1 in HiB5 hippocampal progenitor cells | |
WO2014189335A1 (fr) | Protéine de fusion comprenant une protéine de liaison à l'annexine a1, protéine p53 et protéine p18 ou p16, et composition pour la prévention ou le traitement du cancer, la comprenant | |
Wilson et al. | Binding of HTLV-1 tax oncoprotein to the precursor of interleukin-16, a T cell PDZ domain-containing protein | |
Lamberti et al. | Analysis of interaction partners for eukaryotic translation elongation factor 1A M-domain by functional proteomics | |
WO2015069044A1 (fr) | Protéine de fusion comprenant la protéine p53 et la protéine p15 liées l'une à l'autre, et composition contenant ladite protéine de fusion pour la prévention ou le traitement du cancer | |
WO2015009082A1 (fr) | Protéine de fusion comprenant la protéine de liaison annexine a2, la protéine p53 et la protéine p18, et composition la contenant pour la prévention ou le traitement du cancer | |
Maruta et al. | Interfering with Ras signaling using membrane-permeable peptides or drugs | |
WO2015069061A1 (fr) | Protéine hybride comprenant la protéine p53 et p16 protéine liées l'une à l'autre, et composition contenant ladite protéine hybride utile pour prévenir ou traiter le cancer | |
CN101096383A (zh) | 表皮生长因子与绿色荧光蛋白的融合蛋白 | |
CN114073760B (zh) | Rdr蛋白在肿瘤治疗中的应用 | |
KR102558985B1 (ko) | Hax1을 포함하는 신경세포 분화 조절용 조성물 및 신경세포 분화 탐지용 바이오마커 | |
WO2022261851A1 (fr) | Application de protéines jaz végétales et de polypeptides dérivés dans la prévention et le traitement de tumeurs humaines et animales | |
Patel et al. | The RET finger protein interacts with the hinge region of SMC3 | |
Boissel et al. | Identification and characterization of the RLIP/RALBP1 interacting protein Xreps1 in Xenopus laevis early development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14800420 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14800420 Country of ref document: EP Kind code of ref document: A1 |